Mitral valve transcatheter edge-to-edge repair (MV-TEER) is increasingly used to treat mitral regurgitation (MR) in patients with heart failure (HF). The benefits of MV-TEER were first validated in the COAPT trial, which showed significantly lower rates of HF hospitalization and all-cause mortality in selected patients who had undergone the procedure compared with guideline-directed medical therapy (GDMT) [ ]. Nevertheless, several trials (eg. Reshape-HF2) investigating the impact of MV-TEER on outcomes, in patients with HF exclusively, remain underway.